Search Ontology:
ChEBI

EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor

Term ID
CHEBI:59897
Synonyms
  • deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (RNA-directed) inhibitor
  • deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (RNA-directed) inhibitors
  • DNA nucleotidyltransferase (RNA-directed) inhibitor
  • DNA nucleotidyltransferase (RNA-directed) inhibitors
  • EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitors
  • EC 2.7.7.49 inhibitor
  • EC 2.7.7.49 inhibitors
  • reverse transcriptase inhibitor
  • reverse transcriptase inhibitors
  • revertase inhibitor
  • revertase inhibitors
  • RNA revertase inhibitor
  • RNA revertase inhibitors
  • RNA-dependent deoxyribonucleate nucleotidyltransferase inhibitor
  • RNA-dependent deoxyribonucleate nucleotidyltransferase inhibitors
  • RNA-dependent DNA polymerase inhibitor
  • RNA-dependent DNA polymerase inhibitors
  • RNA-directed DNA polymerase (EC 2.7.7.49) inhibitor
  • RNA-directed DNA polymerase (EC 2.7.7.49) inhibitors
  • RNA-directed DNA polymerase inhibitor
  • RNA-directed DNA polymerase inhibitors
  • RNA-instructed DNA polymerase inhibitor
  • RNA-instructed DNA polymerase inhibitors
  • RT inhibitor
  • RT inhibitors
  • telomerase inhibitor
  • telomerase inhibitors
(all 27)
Definition
A DNA polymerase inhibitor that interferes with the activity of reverse transcriptase, EC 2.7.7.49, a viral DNA polymerase enzyme that retroviruses need in order to reproduce.
References
Ontology
ChEBI  ( EBI )
Relationships
is a type of
inverse has_role
Phenotype
Phenotype resulting from EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
Phenotype where environments contain EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
Phenotype modified by environments containing EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
Phenotype affecting EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
Human Disease Model
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.